Halozyme Therapeutics Revenue by Segment

Period Ending	Mar 31, 2025	Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023
Royalties	618.59M	570.99M	522.62M	482.00M	468.82M	447.87M	431.79M	416.91M
Royalties Growth	31.95%	27.49%	21.04%	15.61%	20.05%	24.24%	36.16%	50.98%
Product Sales	322.95M	303.49M	303.73M	303.64M	298.64M	300.85M	282.42M	257.27M
Product Sales Growth	8.14%	0.88%	7.55%	18.02%	30.02%	57.49%	79.98%	113.44%
Revenues Under Collaborative Agreements	142.77M	140.84M	121.00M	87.67M	95.53M	80.53M	66.50M	99.47M
Revenues Under Collaborative Agreements Growth	49.45%	74.88%	81.95%	-11.86%	12.67%	-25.85%	-37.60%	9.55%

Operating Expense Breakdown

Period Ending	Mar 31, 2025	Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023
Cost of Sales	179.49M	159.42M	169.66M	175.06M	185.52M	192.36M	182.18M	174.68M
Cost of Sales Growth	-3.25%	-17.13%	-6.87%	0.22%	17.01%	38.09%	53.39%	94.00%
Selling, General, and Administrative	161.56M	154.34M	149.69M	143.72M	146.96M	149.18M	149.32M	148.52M
Selling, General, and Administrative Growth	9.94%	3.45%	0.25%	-3.23%	-12.03%	3.94%	24.90%	51.16%
Research and Development	74.74M	79.05M	79.94M	78.81M	77.50M	76.36M	77.59M	76.98M
Research and Development Growth	-3.56%	3.52%	3.03%	2.38%	6.55%	14.65%	43.30%	67.60%
Amortization	71.05M	71.05M	71.05M	73.63M	73.70M	73.77M	60.56M	67.42M
Amortization Growth	-3.60%	-3.69%	17.31%	9.22%	20.85%	70.98%	56.92%	491.20%

Source: Business metrics provided by Main Street Data and sourced from official company press releases and documents.